Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02796729 : CEST- Glucose Enhanced MRI for Metastatic Brain Tumours
PhasePhase 2
AgesMin: 18 Years Max: 65 Years
Inclusion Criteria:

- Male or females

- Between 18 and 65 years of age

- Of all ethnic groups

- BCCA participants with at least one contrast enhancing brain mass with a diameter = 1
cm and consistent with metastatic carcinoma*

- Able to give consent

- Willingness to participate in the study * One additional healthy participant will be
included in the study to perform a 'test-run' for the complicated MRI and infusion

Exclusion Criteria:

- Pregnancy

- Diabetes mellitus (self-reported or HbA1C = 6.5%)

- Ferromagnetic implant or foreign metallic bodies (pacemaker, loose metal, etc.)

- Claustrophobia

- History of kidney disease and/or eGFR < 60

- Abnormal fasting blood glucose (<70mg/dL or >125 mg/dL)

- Allergic to corn

- History of adverse reactions to gadolinium based contrast agents

- Poor performance status (Karnofsky PS<70%)

- Previously received whole brain radiotherapy

- All lesions evident on imaging were previously treated with stereotactic radiosurgery

- The participants weigh more than 300lbs

- The participants had surgery in the last 6 weeks

- The participants have an intrauterine device

- The participants have cosmetic tattoos
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557